Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL, check tomorrow. Once filed, usually takes a few days. Let's hold off on any negativity until we know for sure, K.
They aren't current, that tweet is a lie. Which means the twitter count is probably a scam. Just someone pumping a dark shell.
New Tweet - SNDZ is now current
Sunridge Int. Inc. ?@SNDZ_2016 15m15 minutes ago
We are excitingly happy to report SNDZ is now current status, PR to follow along with business venture merger details.
https://twitter.com/SNDZ_2016
Looking good, go SNDZ!
CDEL might cause this to go to .05 all my himself.
Looks like CDEL is freaking out. He may be a short in severe trouble. I've got some guys coming with money to slam the ask. He's screwed.
With how thin the L2 is and with how low the float is, this could easily go to multiple pennies in coming days. Incredibly fast moving.
$SNDZ
This week? Nice.
From Twitter:
"Thank you for all the calls and questions we received yesterday, we appreciate it. Everything is coming along, updates later this week."
picked up a starter here DJ
6.9 million in float. This should really soar on news.
Up 80% on air. Can't imagine how hard this will run with volume. Looking really good here.
"We are close to becoming current, approval expected within the week. Stay tuned for news about a new business venture and potential merger." ~ from Twitter
I saw it this morning too, which is the reason why I bought some. They tweeted a few week back too.
@SNDZ_2016
It says this week too. I'm expecting more investors to find this soon. This could be the lotto play of the year. Spread the word!
Great find. I was wondering why SNDZ was finally moving higher.
Anyone else see this???? https://twitter.com/SNDZ_2016
Heavy volume and buying in SNDZ in the last 30 minutes. Anyone know anything?
Hoping to see some filings, until then, theres nothing really here
The co. sold off the assets and paid off the debt, per filing. I think it's just an empty clean shell
They are not current, wonder what happened to that deal.
Thoughts on SNDZ? Seems like a clean shell with no debt?
Assets sold off in 2012. Volume is intriguing...
On April 10, 2012, Sunridge International, Inc. (the “Company”) entered into an Asset Purchase Agreement (the Agreement”) with Westhouse Medical Services, PLC (“Westhouse”) whereby the Company will sell all of the Company’s patents, products, and contracts as described in the Agreement for $2,000,000, in the aggregate. Westhouse will provide $1,000,000 in bank certified funds upon closing and $1,000,000 in Westhouse corporate bonds that mature three years from the date of issuance with an annual interest coupon of 7% attached to the bonds payable annually. As a part of the Agreement, the Company shall retain the exclusive right to distribute the Company products in Canada. Once the closing is completed, Sunridge will pay off existing debt as well as get current with it SEC filings, and then move forward with opening the first glaucoma treatment center in Canada. With the funds in place, Sunridge has the ability to implement its business plan and become a profitable company.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8547802
Lmfao I posted here 2012, im getting ihub old
SNDZ woke up today
SNDZ nice to see some talk about them. could be big if they start to move forward with opening locations. small enough float and outstanding shares to possibly move by the pennies!
Hope they get current soon. Filings should get this thing in the air. Mix that with a tiny float, thin L2, company plan we may have something here.
SNDZ spoke to CEO:
1. Filings coming, first form 15 then quarterly filings.
2. opening 2 clinics one in London and one in Canada. They have half the money already from investors and are speaking with investors for the rest of the money.
3. Company currently manufactures and sells their patented medical products.
4. Guy talked alot and seemed very honest call him yourself! Phone: 480-837-6165
5. Float only 6,900,000 a/o Sep 01, 2010
6. They are not planning on selling shares!
any idea what the form 25 filed last month means here?
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9588341
CAUTION...Do your DD. Old ticker was CDIK.
New company name, old company players.
Check out what happened to old shareholders.
PNT and Smith management was BAD news.
Coronado Industries was old name, ticker CDIK.
Beware... note share printing for management compensation.
Does Anybody know whats going on with this Company?????
i wish there was more info on this
all i know is what the PR says
so when is the closing date for the buyout / sale ??
Thanks.
MrMiyagi, Iv'e been reading this with alot of interest. Do you think now is a good time to buy SNDZ stock ? ... The Westhouse buy out should be good for the SNDZ pps going forward I would think ?
Thanks for any feedback .....
IMO.
Iv'e been reading this with alot of interest. Do you think now is a good time to buy SNDZ stock ? ... The Westhouse buy out should be good for the SNDZ pps going forward I would think ?
Thanks ...
IMO.
this good be good for us shareholders after Richard Smith screwed us he is out http://www.privateequitywire.co.uk/2012/03/08/163355/westhouse-medical-services-negotiation-acquire-majority-control-sunridge-internati
The Dean is pumping this he was paid $5,000.00 pump and dump garbage stock
FOUNTAIN HILLS, Ariz., Oct 07, 2010 /PRNewswire via COMTEX/ -- Sunridge International (OTC Bulletin Board: SNDZ) said today that its patented Pneumatic Trabeculoplasty (PNT) non-invasive treatment for glaucoma and ocular hypertension, is making its mark in China. Introduced into China by Beijing Vision World Trading Co. Ltd. (BVW), in 2007, the PNT treatment has undergone the most vigorous patient research studies before gaining regulatory approval by China's Federal Drug Administration earlier this year.
In recent months, Beijing Vision World had presented the PNT treatment at a number of ophthalmologist conferences, expert forums and hospital training seminars in a number of cities throughout China including Beijing, Nanjing, Taiyuan, Wuhan, Changsha and several towns throughout Northeast China. Research papers devoted to PNT have been presented by leading ophthalmic practitioners and academics at several conferences all of which have been reported in news articles and feature stories appearing in China's general and technical publications. Details of the treatment and its impact on glaucoma patients, have been featured on national TV programs. More information regarding these events can be viewed at www.visionworld.com.cn.
In summarizing his firm's progress, Mr. Yang Waisheng, President of BVW, said he and his marketing team were extremely pleased with the reception given by some of China's most demanding ophthalmologists, eye doctors and hospitals throughout China. "We have made a very good start and it is our intention to continue to demonstrate the PNT approach to the treatment of glaucoma. Our goal is to have PNT taken up by an increasing number of hospitals, clinics and ophthalmic surgeries in China so that we might reach out to as many glaucoma sufferers as possible throughout this vast country. We are conscious of the fact that many of these patients would otherwise be unable to find treatment to control this pervasive eye disease which is so prevalent in China."
G. Richard Smith, CEO of Sunridge International, said that China represents an enormous marketing opportunity for the PNT equipment and treatment. "We are delighted with the progress and sales made by Mr. Yang and his team each month and we are determined to provide maximum sales and marketing support to bear on their efforts to bringing our treatment to the tremendous number of outlets in China."
FOUNTAIN HILLS, Ariz., Oct 04, 2010 /PRNewswire via COMTEX/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that successful negotiations have concluded with the signing of exclusive distribution rights to its PNT product line in Bangladesh. The agreement has been reached between Sunridge and New Amsterdam Marketing (NAM), its current exclusive distributor in India.
"There has been a large increase in interest in our PNT product line and glaucoma treatment, ever since NAM starting its marketing rollout in neighboring India last month," states G. Richard Smith, CEO of Sunridge. Mr. Smith goes on to say, "that NAM's marketing plan is both impressive and aggressive, and that their sales have already surpassed original estimates."
"Bangladesh is the sixth largest country in the world by population, and should be a major market for our two-minute non-invasive glaucoma treatment, and a significant revenue stream for our company," states Mr. Smith.
Leo D. Bores, M.D., a medical consultant for Sunridge, will be traveling throughout India for the next two weeks working with NAM's personnel, training doctors, treating patients and providing informational seminars to the public. NAM's personnel have stated, that Dr. Bores's schedule will likely be changed to include stops in Bangladesh.
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).
FOUNTAIN HILLS, Ariz., Sept 28, 2010 /PRNewswire via COMTEX/ -- Sunridge International (OTC Bulletin Board: SNDZ) said today that their treatment for glaucoma and ocular hypertension will be introduced in October to eye doctors and the medical community in India.
Presentations have been planned by its Indian distributors, New Amsterdam Marketing Corporation, in major cities from October 1 - 14. The company's Pneumatic Trabeculoplasty (PNT), treatment is a cost-effective, non-invasive procedure designed to reduce pressure on the retinal nerve. The two-minute procedure, easily performed in a clinic or doctors office, is required only three or four times a year. It is a treatment regime that is especially valuable to patients in rural areas, where traditional medical facilities are limited.
Sunridge International, the developer and marketer of the PNT treatment, announced today that it's exclusive marketer in India, will be holding meetings to demonstrate the procedure to hundreds of medical personnel throughout the country.
The first presentations will be held at the (www.apos.in) conference in Hyderabad from October 1-3. This will be followed by meetings in Calcutta, Mumbai and Jaipur. The presentations will be led by Dr. Leo Bores, M.D. Dr. Bores also will be holding private meetings over a two week period in India.
G. Richard Smith, CEO of Sunridge International, said the company was especially pleased to be able to bring the PNT procedure to India. "We are introducing our PNT equipment and treatments in many markets throughout the world, including the European Union countries, China and Latin America. But India is a very special place. It offers enormous opportunity for us."
"Working with New Amsterdam colleagues, we look forward to helping, perhaps, thousands of people suffering from glaucoma and ocular hypertension throughout the country. Often in the rural countryside, with a very poor population, glaucoma is left untreated. For many the cost of ongoing treatment is simply out of their reach. We strongly believe that PNT provides an answer to this problem, and gives people an opportunity for a safe, effective and affordable treatment.
"We will be giving the doctors and medical personnel attending the New Amsterdam presentations our fullest support and look forward to a long and mutually rewarding association with them."
Glaucoma is the second leading cause of blindness, affecting more than 70 million people worldwide. Studies completed over the last 10 years have proven that PNT is a safe effective and cost effective alternative treatment for glaucoma and ocular hypertension. The two-minute treatment has been developed, patented and distributed by Sunridge International's wholly-owned subsidiary, Ophthalmic International.(www.oi-pnt.com).
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2071
|
Created
|
01/15/10
|
Type
|
Free
|
Moderators |
Outstanding Shares 40,000,000
Float 2M
Sunridge International Inc. (SNDZ.OB) Fully Reporting
http://www.sunridgeint.com
52 wk. High | 2.00 | 52 wk. Low | 0.35 |
Sunridge International, Inc engages in the manufacture and marketing of a fixation device in Canada and Europe. It provides vacuum fixation device and a patented design suction ring for the treatment of open angle glaucoma. The company was founded in 1997 and is based in Fountain Hills, Arizona.
Company Officers
Victor Webb, Dir.
Theodore Tsagkaris, Dir.
John Sharkey, Dir.
G. Richard Smith, Dir., CEO, President
Gary R. Smith, CFO, Treasurer, SecretaryWholly owned subsidary:
Ophthalmic International
Ophthalmic International is headquartered near
Phoenix, Arizona and has a European office near
Rome, Italy. The company's focus is on the
development and commercialization of Pneumatic
Trabeculoplasty (PNT), a non-invasive treatment
for open angle glaucoma (OAG) and ocular
hypertension (OH).
EQUIPMENT
PNeumatic Trabeculoplasty (PNT) Vacuum
Ring.
The PNT Vacuum Ring is a sterilized single-use
disposable ring which is designed for use with
the Model 1000 PNT Vacuum Controller. Both
the equipment and procedure are covered by
patents in all major markets including the
United States, Europe, Japan, Australia, China
The Model 1000 with integrated bar code
reader and vacuum display
Ophthalmic International has been granted a 2a CE
mark for both the Model 1000 Pneumatic
Trabeculoplasty (PNT) Vacuum Controller and
PNeumatic Trabeculoplasty (PNT) Suction Ring
allowing for the sale of the equipment within the
European Economic Community. This PNeumatic
Trabeculoplasty (PNT) equipment is the only
equipment approved for performing Pneumatic
Trabeculoplasty (PNT) within the EEC
WHAT'S NEXT
After ten years research, development and testing and an $12-million investment, they are now moving towards full-scale, worldwide distribution. That begins with explaining the procedures to the specialists who treat glaucoma and obtaining approvals from healthcare authorities around the world. Their business plan for the period 2010-2014 projects total revenues for the five-year period of $240 million, with over $163 million in net earnings before taxes. For accredited investors, this represents a very attractive investment proposition that commends itself for immediate consideration.
MARKETING
Distribution agreements are already in place for France, Italy, Spain, Portugal, Poland, Serbia, Canada, and China. They are in negotiations fordistribution to the remainder of the EU, Turkey, and Brazil. To date, their distributors have invested over $6.3 million in international market development.
Published Article in
HealthNewsDigest.com
The Vision Thing--For Real
By Michael D. Shaw, Contributing Columnist - HealthNewsDigest.com
Jan 24, 2010 - 1:00:00 AM
(HealthNewsDigest.com) - It is most interesting that the word "vision" refers both to the sense of sight, as well as to something perceived in a manner other than through one's eyes. When presidential candidate George H.W. Bush asked a friend to help him identify some important issues for the upcoming campaign in 1988, it was suggested that Bush spend some time at Camp David to set his own presidential agenda. Apparently unimpressed by his friend's advice, Bush—long experienced with nitty gritty details, but sometimes lacking in gauging the big picture, or at least having difficulties in expressing it—sardonically replied, "Oh, the vision thing." The big picture on glaucoma—the so-called "sneak thief of sight" since it has few early symptoms—is that this group of diseases represents the second leading cause of blindness (second only to diabetes). Vision loss derives from damage to the optic nerve, frequently identified with elevated intraocular pressure (IOP). IOP is directly related to the amount of fluid (aqueous humor) within the eye, and can build up if the drainage system (trabecular meshwork) is not functioning properly.
The Glaucoma Research Foundation points out that early detection, through regular and complete eye exams, is the key to protecting your vision from damage caused by glaucoma. Typical tests are tonometry, in which the IOP is measured, and ophthalmoscopy, whereby the interior of the eye—including the optic nerve—can be examined. For those with the disease, typical treatment modalities involve medications such as eye drops or pills that act to lower the IOP, along with laser and conventional surgical intervention. Laser trabeculoplasty (remember that trabecular meshwork?) promotes better drainage. Conventional surgery creates actually creates a new opening for drainage. As with all drugs and surgical procedures, side effects and complications can occur. For some patients, compliance with the dosage schedule of the eye drops is a problem. One novel therapy, called Pneumatic Trabeculoplasty (PNT), has been introduced by Ophthalmic International [http://www.oi-pnt.com], a subsidiary of Sunridge International. PNT is described by the company as a non-invasive, cost effective, alternative treatment for glaucoma and ocular hypertension, performed in the doctor's office, under local (topical) anesthetic. PNT utilizes a vacuum fixation ring connected to a computerized vacuum controller. The ring is placed on the surface of the eye—held open by a speculum— and a vacuum is applied for one minute. Five minutes later, the procedure is repeated; and this process can be reprised one week later, for even better results. IOP is checked one hour after the procedure. The duration of the IOP lowering effect is, on average, three to four months—at which time the procedure can be repeated. While PNT is approved in several countries outside of the United States (including Canada and the EEC), the product is under development here, and therefore is still considered an investigational device under current FDA regulations. Additional clinical trials are planned. A number of recent studies attest to the safety and efficacy of PNT. Approximately 75% of patients will exhibit an IOP reduction following PNT. Patients reported no serious side effects to vision and no changes in the visual field or optic nerve head. PNT can also be used for newly diagnosed patients who have yet to undergo pharmaceutical approaches. Given the number of people affected by glaucoma, it is comforting that well over 100 clinical trials—implementing all sorts of therapies—are currently recruiting patients. For more information, visit NIH's registry [http://www.clinicaltrials.gov.] The Glaucoma Research Foundation (GRF) also details advances in glaucoma treatment [http://www.glaucoma.org/treating/advances.php].
GRF recommends the following examination schedule:
Distributors of Pneumatic
Trabeculoplasty (PNT) Equipment
Recent News | ||||
Date | Time |
| ||
02/22/2010 | 4:40PM | Quarterly Report (10-Q) | ||
02/22/2010 | 9:00AM | Sunridge International to Present to the Long Island Investment Banking Group | ||
02/16/2010 | 12:10PM | Notification that Quarterly Report will be submitted late (NT 10-Q) | ||
02/05/2010 | 11:19AM | Chinese Distribution Contract Extended for an Additional 4 Years | ||
02/02/2010 | 10:17AM | Luis Tiant and Sunridge International Partner to Provide Medical Relief in Cuba: Former Star Pitcher for the Red Sox and Yankees | ||
01/26/2010 | 9:00AM | Sunridge International's Patented 'PNT' Procedure is Topic of Health News Digest Recent Article | ||
01/19/2010 | 9:00AM | Sunridge International Corporate Update | ||
01/13/2010 | 9:15AM | Sunridge International Introduces Its New Wholly Owned Subsidiary | ||
11/19/2009 | 5:17PM | Quarterly Report (10-Q) | ||
11/16/2009 | 9:56AM | Notification that Quarterly Report will be submitted late (NT 10-Q) | ||
10/05/2009 | 6:01AM | Current report filing (8-K) |
Contact SNDZ.OB
Sunridge International, Inc
16857 E. Saguaro Blvd.
Fountain Hills, AZ 85268 USA
(t) +1 480 837 6165
(f) +1 480 837 6870
email - inquiries@oi-pnt.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |